Skip to main content

RTAD Platform for Innovative Biologic Drug Products

Room Temperature Aerosol Dehydration (RTAD)

A scalable and cGMP-compatible biopharmaceutical technology that converts liquid biologics into room-temperature-stable drug formulations and enables various routes of administration.

RTAD unlocks continuous production of biological therapies as powder and suspension drug formulations, enabling unprecedented formulation flexibility for pharma, public health and defense applications.

Why RTAD Changes the Equation

Capabilities that Conventional Biopharmaceutical Technologies Cannot Unlock

Ultra-Concentrated >500 mg/mL mAbs

Subcutaneous injections of monoclonal antibodies

PATIENT BENEFITS

  • Reduces administration time by hours
  • Enables at-home self-administration
  • Saves $150-200K ann. per patient

PHARMA BENEFITS

  • Ultra-conc. >500 mg/mL mAbs
  • Broader molecule landscape
  • Franchise extension vs. biosimilars

Cold Chain-Free Biologics

Room Temperature Stability

PATIENT BENEFITS

  • Global access & distribution
  • Emerging market deployment
  • Simplified storage

DEFENSE/GOV BENEFITS

  • Field deployment capability
  • Strategic stockpile ready
  • Logistics elimination

Inhaled Biologics and Vaccines

Administered with Dry Powder Inhaler

PATIENT BENEFITS

  • Eliminates cold chain requirements
  • Convenient pulmonary delivery
  • Global accessibility

PHARMA BENEFITS

  • 5-10x production capacity gain
  • Reduced FDA risk & timeline
  • Broader molecule landscape

Intranasal Biologics and Vaccines

Administered with Nasal Spray & Powder Device

PATIENT BENEFITS

  • Non-invasive administration
  • Rapid absorption
  • Room-temperature storage

PHARMA BENEFITS

  • Non-invasive administration
  • Rapid absorption
  • Room-temperature storage

Why RTAD Changes the Equation

Capabilities that Conventional Biopharmaceutical Technologies Cannot Unlock

Enabling Biologic Formulations

Biologics that fail traditional drying-based formulation succeed with RTAD, achieving 10–100× less dehydration-induced damage to biologics.

Manufacturing De-Risk

Retrofit existing cGMP spray dryers instead of investing over $50M in greenfield facilities. RTAD offers a 12–18 month proven scale-up with digital twin validation.

Operational Capability

Room-temperature stability enables field deployment, creation of strategic stockpiles, and surge manufacturing for defense readiness.

Franchise Protection

Formulation IP blocks biosimilars for 5–7 years. Extend aging franchises against $120B patent cliffs through 2030.

Capacity Gains

Achieve 5–10× manufacturing capacity from existing infrastructure. Digital twin CFD predictive modeling helps to de-risk the scale-up process.

Speed to Clinic

RTAD provides a proven 100× feedstock scale-up within 12–18 months, compared to over 24 months for alternative methods. The consistent process is aligned with FDA-ready CMC standards.

Validation & Commercial Traction

Technical achievements, pharma validation and Market proof

SuspensiFlow Proven

>500 mg/mL mAb, 27G needle, <10N injection force, no aggregates

100× Scale-Up

Consistent droplet size across 1→100 mL/min feedstock increase. Digital twin CFD validated.

Partnerships

Merck Digital Sciences Studio completed. Feasibility studies in negotiation for SC program.

Industry Validation

10× inhaled capacity validated by Top 10 Pharma company. Joint study on scale-up to pilot production is underway.

Technology from Princeton University

Exclusive license on core tech. 10+ peer-reviewed publications. Patents through 2040s.

Awards and Non-Dilutive Funding

NSF SBIR Phase I and II, NIH STTR Phase I, DoW SBIR Phase I, NJ CSIT backing. Market validation via government agencies.

Read the latest news

Inaedis Selected for Merck Digital Sciences Studio Cohort

Inaedis Selected for Merck Digital Sciences Studio Cohort

PRESS RELEASE Princeton, NJ, Nov 19, 2024 – Inaedis is proud to announce its acceptance into the latest cohort of…
Inaedis Wins Prestigious NSF SBIR Phase II Award to Revolutionize Biologic Drug Stability

Inaedis Wins Prestigious NSF SBIR Phase II Award to Revolutionize Biologic Drug Stability

PRINCETON, NEW JERSEY (June 17, 2025) – Inaedis, Inc. is thrilled to announce it has been awarded a highly competitive $1.25…
Inaedis Awarded Competitive SBIR Phase I Contract from the U.S. Department of Defense

Inaedis Awarded Competitive SBIR Phase I Contract from the U.S. Department of Defense

DoD SBIR Program Provides Funding to Advance Thermostable Biologic and Vaccine Formulations PRINCETON, NEW JERSEY – September 8, 2025 – Inaedis…

Supported by

Join us in transforming biologics delivery

Ready to explore collaboration, investment, or new applications of RTAD?